3SBio Inc. Posts Phase II NSCLC Data: mPFS ~13.6–13.8 Months

What happened

3SBio reported Phase II data for tivunatamig plus chemotherapy in first-line advanced NSCLC. Median progression-free survival was 13.6 months in squamous and 13.8 months in non-squamous patients, with response rates of 80.7% and 77.5% versus controls.

Confirmed

Global impact / market context

Longer progression-free survival, which means time before disease worsens, versus control suggests the drug may work. Strong response rates support a Phase III trial, and success there could lead to regulatory approval and future revenue for 3SBio.

Analyst inference

The drug was out-licensed to Pfizer, giving a large partner with many trial sites, which may speed development. Positive mid-stage data can raise expectations for the next trial and potential future sales.

Analyst inference

What to watch

1. Watch for Phase III trial results for tivunatamig plus chemotherapy, since the company says positive well-powered Phase III data and regulatory filings would be a major commercial catalyst. Confirmed
2. Track whether Pfizer advances the drug through its planned trials and sites, because a larger partner could speed enrollment and bring the treatment closer to regulatory review. Proposed
3. Monitor safety updates, especially serious side effects, since comparable safety to control supports the idea that added efficacy does not come with new major treatment risks. Analyst inference

Evidence

• Original source link unavailable